Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, Norrbacka S1:02, Stockholm SE 17177, Sweden.
Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, Norrbacka S1:02, Stockholm SE 17177, Sweden; Heart, Vascular and Neuro Theme, Department of Cardiology, Karolinska University Hospital, Anna Steckséns gata 41, 171 64 Solna, Sweden.
Heart Fail Clin. 2022 Oct;18(4):551-559. doi: 10.1016/j.hfc.2022.03.009.
Sodium-glucose cotransporter 2 inhibitors were first discovered as glucose-lowering drugs because of their glycosuric action and good safety profile. Subsequently, they were studied in cardiovascular outcome trials in people with type 2 diabetes, and their cardiovascular benefit was consistently observed as regards heart failure hospitalizations and cardiovascular death. Investigation of the underlying mechanisms granting such benefit is continuously engaging researchers all over the world. The findings described in this article paved the way to a larger use of these drugs in patients with heart failure, with the aim of improving their clinical outcomes and quality of life.
钠-葡萄糖共转运蛋白 2 抑制剂最初因其降血糖作用和良好的安全性而被发现是一种降糖药物。随后，在 2 型糖尿病患者的心血管结局试验中对其进行了研究，一致观察到它们在心衰住院和心血管死亡方面具有心血管益处。对赋予这种益处的潜在机制的研究不断吸引着世界各地的研究人员。本文描述的研究结果为在心力衰竭患者中更广泛地使用这些药物铺平了道路，旨在改善他们的临床结局和生活质量。
